GTG shares soar on back of Applera lawsuit news
20 September, 2004 by Renate KrelleThe share price of Genetic Technologies (ASX: GTG) has risen over 50 per cent since the judge in GTG's lawsuit against Applera ruled largely in the company's favour during the Markman hearing last Thursday.
Isis antisense drug delays tumour growth
17 September, 2004 by Staff WritersShares of California-based Isis Pharmaceuticals rose as much as 13 per cent on Thursday after it said its experimental anti-cancer compound significantly delayed tumour growth and increased the rate of malignant cell death in cell and animal models.
New NZ fund set up for agbiotech investment
17 September, 2004 by Renate KrelleA New Zealand-based venture capital fund of between NZ$75-100 million (AUD$70-94.5 million), with a focus on agricultural biotech has been established by the venture capital arm of the NZ government and private collaborators Direct Capital and crown research institute AgResearch.
Avastra investigates using Bioweld for drug deliery
17 September, 2004 by Melissa TrudingerNSW biomaterials company Avastra (ASX: AVS) is investigating the potential of its BioWeld technology -- which uses a protein solder activated by laser light to fuse together blood vessels -- as a drug delivery mechanism.
Biota launches share purchase plan
16 September, 2004 by Melissa TrudingerBiota (ASX:BTA) has launched a share purchase plan, which could raise almost AUD$15 million for the company if fully subscribed.
Imugene expands technology opps with new company
16 September, 2004 by Melissa TrudingerImugene (ASX:IMU) and the University of Adelaide have set up a new company to develop and commercialise human gastrointestinal applications of the receptor mimic technology (RMT), including cholera, rotavirus, 'travellers' diarrhoea', and antibiotic-associated diarrhoea.
Benitec using RNAi to focus on hep C
15 September, 2004 by Graeme O'NeillA senior scientist from Brisbane-based biotech company Benitec (ASX:BLT) has told a conference that there is "incredible excitement" in the biomedical research community about the human therapeutic potential of RNA interference (RNAi) gene-silencing technology.
Chemgenex patents more depression genes
15 September, 2004 by Melissa TrudingerChemGenex Pharmaceuticals (ASX: CXS) has filed patent applications for another five novel depression-associated gene targets, bringing the total number of gene targets with patent protection from the CNS project to 10.
Capital injection advances Rockeby's marketing plans
14 September, 2004 by Melissa TrudingerRockeby Biomed (ASX:RBY) has secured AUD$3 million from institutional and high net worth investors including current investors Queensland Investment Corporation and Thorney Holdings, which will both increase their holdings to become substantial shareholders.
Biology's central dogma goes out with the junk
14 September, 2004 by Graeme O'NeillJohn Mattick, director of the Institute for Molecular Biosciences at the University of Queensland, has told an international RNAi conference that biology's central dogma is wrong -- at least as it applies to higher organisms.
Bone upbeat after trial results
13 September, 2004 by Renate KrelleThe ambitions of Bone Medical (ASX:BNE) to bring the first oral version of osteoporosis drug calcitonin to the world market moved closer today, when the company announced encouraging results from a Phase I/IIa study of its lead candidate BN002.
Clients, kudos for Genetic Solutions
13 September, 2004 by Staff WritersBrisbane-based biotech Genetic Solutions has earned a new client and an accolade at the 2004 Premier of Queensland Smart Awards.
Peptech, Genera rumours premature
13 September, 2004 by Renate KrelleReports of Peptech's (ASX:PTD) impending takeover of tiny DNA-analysis company Genera Biosystems are premature, according the heads of both companies.
Ventracor starts global trial with implant in Perth
13 September, 2004 by Staff WritersVentracor (ASX:VCR) has begun a global trial of its VentrAssist device, with the implant of a patient suffering congestive heart failure at Royal Perth Hospital.
In brief: ResMed, Genesis, Genepharm, EG Capital
10 September, 2004 by Staff WritersSleep disorder specialist company ResMed (ASX:RMD) has promoted Kieran Gallahue from president and American chief operating officer to president of ResMed Global.
